<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39312164</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1940-6029</ISSN><JournalIssue CitedMedium="Internet"><Volume>2834</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Methods in molecular biology (Clifton, N.J.)</Title><ISOAbbreviation>Methods Mol Biol</ISOAbbreviation></Journal><ArticleTitle>Approaching Pharmacological Space: Events and Components.</ArticleTitle><Pagination><StartPage>151</StartPage><EndPage>169</EndPage><MedlinePgn>151-169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-0716-4003-6_7</ELocationID><Abstract><AbstractText>The pharmacological space comprises all the dynamic events that determine the bioactivity (and/or the metabolism and toxicity) of a given ligand. The pharmacological space accounts for the structural flexibility and property variability of the two interacting molecules as well as for the mutual adaptability characterizing their molecular recognition process. The dynamic behavior of all these events can be described by a set of possible states (e.g., conformations, binding modes, isomeric forms) that the simulated systems can assume. For each monitored state, a set of state-dependent ligand- and structure-based descriptors can be calculated. Instead of considering only the most probable state (as routinely done), the pharmacological space proposes to consider all the monitored states. For each state-dependent descriptor, the corresponding space can be evaluated by calculating various dynamic parameters such as mean and range values.The reviewed examples emphasize that the pharmacological space can find fruitful applications in structure-based virtual screening as well as in toxicity prediction. In detail, in all reported examples, the inclusion of the pharmacological space parameters enhances the resulting performances. Beneficial effects are obtained by combining both different binding modes to account for ligand mobility and different target structures to account for protein flexibility/adaptability.The proposed computational workflow that combines docking simulations and rescoring analyses to enrich the arsenal of docking-based descriptors revealed a general applicability regardless of the considered target and utilized docking engine. Finally, the EFO approach that generates consensus models by linearly combining various descriptors yielded highly performing models in all discussed virtual screening campaigns.</AbstractText><CopyrightInformation>© 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vistoli</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmaceutiche, Università Degli Studi di Milano, Milan, Italy. giulio.vistoli@unimi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talarico</LastName><ForeName>Carmine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>EXSCALATE, Dompé Farmaceutici SpA, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vittorio</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmaceutiche, Università Degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunghini</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>EXSCALATE, Dompé Farmaceutici SpA, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzolari</LastName><ForeName>Angelica</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmaceutiche, Università Degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beccari</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>EXSCALATE, Dompé Farmaceutici SpA, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Farmaceutiche, Università Degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Methods Mol Biol</MedlineTA><NlmUniqueID>9214969</NlmUniqueID><ISSNLinking>1064-3745</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="Y">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Binding space</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword><Keyword MajorTopicYN="N">Molecular flexibility</Keyword><Keyword MajorTopicYN="N">Pharmacological space</Keyword><Keyword MajorTopicYN="N">Sars-CoV-2 M-Pro</Keyword><Keyword MajorTopicYN="N">TRPM8</Keyword><Keyword MajorTopicYN="N">Toxicity prediction</Keyword><Keyword MajorTopicYN="N">Virtual screening</Keyword><Keyword MajorTopicYN="N">hERG</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39312164</ArticleId><ArticleId IdType="doi">10.1007/978-1-0716-4003-6_7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vistoli G, Pedretti A, Mazzolari A et al (2018) Approaching pharmacological space: events and components. Methods Mol Biol 1800:245–274</Citation><ArticleIdList><ArticleId IdType="pubmed">29934897</ArticleId><ArticleId IdType="doi">10.1007/978-1-4939-7899-1_12</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron G, Digiesi V, Solaro S et al (2020) Flexibility in early drug discovery: focus on the beyond-rule-of-5 chemical space. Drug Discov Today 25:621–627</Citation><ArticleIdList><ArticleId IdType="pubmed">31991117</ArticleId><ArticleId IdType="doi">10.1016/j.drudis.2020.01.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Vistoli G, Pedretti A, Villa L et al (2005) Solvent constraints on the property space of acetylcholine. I Isotropic solvents. J Med Chem 48:1759–1767</Citation><ArticleIdList><ArticleId IdType="pubmed">15771422</ArticleId><ArticleId IdType="doi">10.1021/jm040823p</ArticleId></ArticleIdList></Reference><Reference><Citation>Vistoli G, Pedretti A, Testa B (2008) Assessing drug-likeness–what are we missing? Drug Discov Today 13:285–294</Citation><ArticleIdList><ArticleId IdType="pubmed">18405840</ArticleId><ArticleId IdType="doi">10.1016/j.drudis.2007.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Vistoli G, Pedretti A, Villa L et al (2005) Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses. J Med Chem 48:4947–4952</Citation><ArticleIdList><ArticleId IdType="pubmed">16033273</ArticleId><ArticleId IdType="doi">10.1021/jm0408969</ArticleId></ArticleIdList></Reference><Reference><Citation>Vistoli G, Pedretti A, Testa B et al (2007) The conformational and property space of acetylcholine bound to muscarinic receptors: an entropy component accounts for the subtype selectivity of acetylcholine. Arch Biochem Biophys 464:112–121</Citation><ArticleIdList><ArticleId IdType="pubmed">17544360</ArticleId><ArticleId IdType="doi">10.1016/j.abb.2007.04.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Barletta GP, Fernandez-Alberti S (2018) Protein fluctuations and cavity changes relationship. J Chem Theory Comput 14:998–1008</Citation><ArticleIdList><ArticleId IdType="pubmed">29262685</ArticleId><ArticleId IdType="doi">10.1021/acs.jctc.7b00744</ArticleId></ArticleIdList></Reference><Reference><Citation>Vistoli G, Mazzolari A, Testa B et al (2017) Binding space concept: a new approach to enhance the reliability of docking scores and its application to predicting butyrylcholinesterase hydrolytic activity. J Chem Inf Model 57:1691–1702</Citation><ArticleIdList><ArticleId IdType="pubmed">28633528</ArticleId><ArticleId IdType="doi">10.1021/acs.jcim.7b00121</ArticleId></ArticleIdList></Reference><Reference><Citation>Beccari AR, Vistoli G (2022) Exscalate4CoV: innovative high performing computing (HPC) strategies to tackle pandemic crisis. Int J Mol Sci 23:11576</Citation><ArticleIdList><ArticleId IdType="pubmed">36232873</ArticleId><ArticleId IdType="pmc">9569893</ArticleId><ArticleId IdType="doi">10.3390/ijms231911576</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiménez-Luna J, Grisoni F, Weskamp N et al (2021) Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin Drug Discov 16:949–959</Citation><ArticleIdList><ArticleId IdType="pubmed">33779453</ArticleId><ArticleId IdType="doi">10.1080/17460441.2021.1909567</ArticleId></ArticleIdList></Reference><Reference><Citation>Slater O, Kontoyianni M (2019) The compromise of virtual screening and its impact on drug discovery. Expert Opin Drug Discov 14:619–637</Citation><ArticleIdList><ArticleId IdType="pubmed">31025886</ArticleId><ArticleId IdType="doi">10.1080/17460441.2019.1604677</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath D (2011) Pharmacophore-based virtual screening. Methods Mol Biol 672:261–298</Citation><ArticleIdList><ArticleId IdType="pubmed">20838973</ArticleId><ArticleId IdType="doi">10.1007/978-1-60761-839-3_11</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia EHB, Assis LC, Oliveira TA et al (2020) Structure-based virtual screening: from classical to artificial intelligence. Front Chem 8:343</Citation><ArticleIdList><ArticleId IdType="pubmed">32411671</ArticleId><ArticleId IdType="pmc">7200080</ArticleId><ArticleId IdType="doi">10.3389/fchem.2020.00343</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Wang H, Zang Y et al (2021) Receptor dynamics in molecular recognition by Cryo-EM and molecular simulation. Comb Chem High Throughput Screen 24:1696–1701</Citation><ArticleIdList><ArticleId IdType="pubmed">33172370</ArticleId><ArticleId IdType="doi">10.2174/1386207323666201110150140</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Rocha SFL, Olanda CG, Fokoue HH et al (2019) Virtual screening techniques in drug discovery: review and recent applications. Curr Top Med Chem 19:1751–1767</Citation><ArticleIdList><ArticleId IdType="pubmed">31418662</ArticleId><ArticleId IdType="doi">10.2174/1568026619666190816101948</ArticleId></ArticleIdList></Reference><Reference><Citation>Réau M, Langenfeld F, Zagury JF et al (2018) Decoys selection in benchmarking datasets: overview and perspectives. Front Pharmacol 9:11</Citation><ArticleIdList><ArticleId IdType="pubmed">29416509</ArticleId><ArticleId IdType="pmc">5787549</ArticleId><ArticleId IdType="doi">10.3389/fphar.2018.00011</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes IA, Pereira FSS, Dardenne LE (2018) Empirical scoring functions for structure-based virtual screening: applications, critical aspects, and challenges. Front Pharmacol 9:1089</Citation><ArticleIdList><ArticleId IdType="pubmed">30319422</ArticleId><ArticleId IdType="pmc">6165880</ArticleId><ArticleId IdType="doi">10.3389/fphar.2018.01089</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanes-Mira C, Fernández-Aguado P, Andrés-López J et al (2022) Comprehensive survey of consensus docking for high-throughput virtual screening. Molecules 28:175</Citation><ArticleIdList><ArticleId IdType="pubmed">36615367</ArticleId><ArticleId IdType="pmc">9821981</ArticleId><ArticleId IdType="doi">10.3390/molecules28010175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Sun H, Shen C et al (2020) Combined strategies in structure-based virtual screening. Phys Chem ChemPhys 22(3149):3159</Citation></Reference><Reference><Citation>Arul Murugan N, Ruba Priya G, Narahari S et al (2022) Artificial intelligence in virtual screening: models versus experiments. Drug Discov Today 27:1913–1923</Citation><ArticleIdList><ArticleId IdType="pubmed">35597513</ArticleId><ArticleId IdType="doi">10.1016/j.drudis.2022.05.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzolari A, Vistoli G, Testa B et al (2018) Prediction of the formation of reactive metabolites by a novel classifier approach based on enrichment factor optimization (EFO) as implemented in the VEGA program. Molecules 23:2955</Citation><ArticleIdList><ArticleId IdType="pubmed">30428514</ArticleId><ArticleId IdType="pmc">6278469</ArticleId><ArticleId IdType="doi">10.3390/molecules23112955</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedretti A, Mazzolari A, Gervasoni S et al (2019) Rescoring and linearly combining: a highly effective consensus strategy for virtual screening campaigns. Int J Mol Sci 20:2060</Citation><ArticleIdList><ArticleId IdType="pubmed">31027337</ArticleId><ArticleId IdType="pmc">6540224</ArticleId><ArticleId IdType="doi">10.3390/ijms20092060</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakubik J, El-Fakahany EE (2020) Current advances in allosteric modulation of muscarinic receptors. Biomolecules 10:325</Citation><ArticleIdList><ArticleId IdType="pubmed">32085536</ArticleId><ArticleId IdType="pmc">7072599</ArticleId><ArticleId IdType="doi">10.3390/biom10020325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzolari A, Gervasoni S, Pedretti A et al (2020) Repositioning dequalinium as potent muscarinic allosteric ligand by combining virtual screening campaigns and experimental binding assays. Int J Mol Sci 21:5961</Citation><ArticleIdList><ArticleId IdType="pubmed">32825082</ArticleId><ArticleId IdType="pmc">7503225</ArticleId><ArticleId IdType="doi">10.3390/ijms21175961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruse AC, Hu J, Kobilka BK et al (2014) Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development. Curr Opin Pharmacol 16:24–30</Citation><ArticleIdList><ArticleId IdType="pubmed">24662799</ArticleId><ArticleId IdType="doi">10.1016/j.coph.2014.02.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedretti A, Granito C, Mazzolari A et al (2016) Structural effects of some relevant missense mutations on the MECP2-DNA binding: a MD study analyzed by Rescore+, a versatile rescoring tool of the VEGA ZZ program. Mol Inform 35:424–433</Citation><ArticleIdList><ArticleId IdType="pubmed">27546046</ArticleId><ArticleId IdType="doi">10.1002/minf.201501030</ArticleId></ArticleIdList></Reference><Reference><Citation>Wishart DS, Feunang YD, Guo AC et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:1074–1082</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1037</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Muñiz R, Bonache MA, Martín-Escura C et al (2019) Recent progress in TRPM8 modulation: an update. Int J Mol Sci 20:2618</Citation><ArticleIdList><ArticleId IdType="pubmed">31141957</ArticleId><ArticleId IdType="pmc">6600640</ArticleId><ArticleId IdType="doi">10.3390/ijms20112618</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Ballester G, Fernández-Carvajal A, Ferrer-Montiel A (2023) Progress in the structural basis of thermoTRP channel Polymodal gating. Int J Mol Sci 24:743</Citation><ArticleIdList><ArticleId IdType="pubmed">36614186</ArticleId><ArticleId IdType="pmc">9821180</ArticleId><ArticleId IdType="doi">10.3390/ijms24010743</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Wu M, Zubcevic L et al (2018) Structure of the cold- and menthol-sensing ion channel TRPM8. Science 359:237–241</Citation><ArticleIdList><ArticleId IdType="pubmed">29217583</ArticleId><ArticleId IdType="doi">10.1126/science.aan4325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y, Le SC, Hsu AL et al (2019) Structural basis of cooling agent and lipid sensing by the cold-activated TRPM8 channel. Science 363:9334</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav9334</ArticleId></ArticleIdList></Reference><Reference><Citation>Talarico C, Gervasoni S, Manelfi C et al (2020) Combining molecular dynamics and docking simulations to develop targeted protocols for performing optimized virtual screening campaigns on the hTRPM8 channel. Int J Mol Sci 21:2265</Citation><ArticleIdList><ArticleId IdType="pubmed">32218173</ArticleId><ArticleId IdType="pmc">7177470</ArticleId><ArticleId IdType="doi">10.3390/ijms21072265</ArticleId></ArticleIdList></Reference><Reference><Citation>Korb O, Stützle T, Exner TE (2009) Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Model 49:84–96</Citation><ArticleIdList><ArticleId IdType="pubmed">19125657</ArticleId><ArticleId IdType="doi">10.1021/ci800298z</ArticleId></ArticleIdList></Reference><Reference><Citation>Beccari AR, Cavazzoni C, Beato C et al (2013) LiGen: a high performance workflow for chemistry driven de novo design. J Chem Inf Model 53:1518–1527</Citation><ArticleIdList><ArticleId IdType="pubmed">23617275</ArticleId><ArticleId IdType="doi">10.1021/ci400078g</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones G, Willett P, Glen RC (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 245:43–53</Citation><ArticleIdList><ArticleId IdType="pubmed">7823319</ArticleId><ArticleId IdType="doi">10.1016/S0022-2836(95)80037-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervasoni S, Talarico C, Manelfi C et al (2022) Extensive sampling of molecular dynamics simulations to identify reliable protein structures for optimized virtual screening studies: the case of the hTRPM8 channel. Int J Mol Sci 23:7558</Citation><ArticleIdList><ArticleId IdType="pubmed">35886905</ArticleId><ArticleId IdType="pmc">9317601</ArticleId><ArticleId IdType="doi">10.3390/ijms23147558</ArticleId></ArticleIdList></Reference><Reference><Citation>Krivov GG, Shapovalov MV, Dunbrack RL Jr (2009) Improved prediction of protein side-chain conformations with SCWRL4. Proteins 77:778–795</Citation><ArticleIdList><ArticleId IdType="pubmed">19603484</ArticleId><ArticleId IdType="pmc">2885146</ArticleId><ArticleId IdType="doi">10.1002/prot.22488</ArticleId></ArticleIdList></Reference><Reference><Citation>Manelfi C, Gossen J, Gervasoni S et al (2021) Combining different docking engines and consensus strategies to design and validate optimized virtual screening protocols for the SARS-CoV-2 3CL protease. Molecules 26:797</Citation><ArticleIdList><ArticleId IdType="pubmed">33557115</ArticleId><ArticleId IdType="pmc">7913849</ArticleId><ArticleId IdType="doi">10.3390/molecules26040797</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannalire R, Cerchia C, Beccari AR et al (2022) Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities. J Med Chem 65:2716–2746</Citation><ArticleIdList><ArticleId IdType="pubmed">33186044</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01140</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Du X, Xu Y et al (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289–293</Citation><ArticleIdList><ArticleId IdType="pubmed">32272481</ArticleId><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Halgren TA, Murphy RB, Friesner RA et al (2004) Glide: a new approach for rapid.; accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759</Citation><ArticleIdList><ArticleId IdType="pubmed">15027866</ArticleId><ArticleId IdType="doi">10.1021/jm030644s</ArticleId></ArticleIdList></Reference><Reference><Citation>McGann M (2011) FRED pose prediction and virtual screening accuracy. J Chem Inf Model 51:578–596</Citation><ArticleIdList><ArticleId IdType="pubmed">21323318</ArticleId><ArticleId IdType="doi">10.1021/ci100436p</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzikov M, Costanzi E, Reinshagen J et al (2021) Identification of inhibitors of SARS-CoV-2 3CL-pro enzymatic activity using a small molecule in vitro repurposing screen. ACS Pharmacol Transl Sci 4:1096–1110</Citation><ArticleIdList><ArticleId IdType="pubmed">35287429</ArticleId><ArticleId IdType="pmc">7986981</ArticleId><ArticleId IdType="doi">10.1021/acsptsci.0c00216</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberg JI, Perry MD, Perrin MJ et al (2012) hERG K(+) channels: structure, function, and clinical significance. Physiol Rev 92:1393–1478</Citation><ArticleIdList><ArticleId IdType="pubmed">22988594</ArticleId><ArticleId IdType="doi">10.1152/physrev.00036.2011</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalluzzi MM, Imbrici P, Gualdani R et al (2020) Human ether-à-go-go-related potassium channel: exploring SAR to improve drug design. Drug Discov Today 25:344–366</Citation><ArticleIdList><ArticleId IdType="pubmed">31756511</ArticleId><ArticleId IdType="doi">10.1016/j.drudis.2019.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido A, Lepailleur A, Mignani SM et al (2020) hERG toxicity assessment: useful guidelines for drug design. Eur J Med Chem 195:112290</Citation><ArticleIdList><ArticleId IdType="pubmed">32283295</ArticleId><ArticleId IdType="doi">10.1016/j.ejmech.2020.112290</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing Y, Easter A, Peters D et al (2015) In silico prediction of hERG inhibition. Future Med Chem 7:571–586</Citation><ArticleIdList><ArticleId IdType="pubmed">25921399</ArticleId><ArticleId IdType="doi">10.4155/fmc.15.18</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanser T, Steinmetz FP, Plante J et al (2019) Avoiding hERG-liability in drug design via synergetic combinations of different (Q)SAR methodologies and data sources: a case study in an industrial setting. J Cheminform 11:9</Citation><ArticleIdList><ArticleId IdType="pubmed">30712151</ArticleId><ArticleId IdType="pmc">6689868</ArticleId><ArticleId IdType="doi">10.1186/s13321-019-0334-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Siramshetty VB, Nguyen D-T, Martinez NJ et al (2020) Critical assessment of artificial intelligence methods for prediction of hERG channel inhibition in the “big data” era. J Chem Inf Model 60:6007–6019</Citation><ArticleIdList><ArticleId IdType="pubmed">33259212</ArticleId><ArticleId IdType="doi">10.1021/acs.jcim.0c00884</ArticleId></ArticleIdList></Reference><Reference><Citation>Asai T, Adachi N, Moriya T et al (2021) Cryo-EM structure of K+-bound hERG channel complexed with the blocker astemizole. Structure 29:203–212.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">33450182</ArticleId><ArticleId IdType="doi">10.1016/j.str.2020.12.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Vittorio S, Lunghini F, Pedretti A et al (2023) Ensemble of structure and ligand-based classification models for hERG liability profiling. Front Pharmacol 14:1148670</Citation><ArticleIdList><ArticleId IdType="pubmed">37033661</ArticleId><ArticleId IdType="pmc">10076575</ArticleId><ArticleId IdType="doi">10.3389/fphar.2023.1148670</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoroso N, Gambacorta N, Mastrolorito F et al (2023) Making sense of chemical space network shows signs of criticality. Sci Rep 13(1):21335. https://doi.org/10.1038/s41598-023-48107-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-48107-3</ArticleId><ArticleId IdType="pubmed">38049451</ArticleId><ArticleId IdType="pmc">10696027</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>